Stock Market 101: Basic strategies investors use to profit off stocks
Before jumping into the market, here’s what first-time investors should know about stocks, capital gains and mistakes to avoid.
For My Money, USA TODAY
It’s tempting to think of all businesses the same way. In reality, companies create all kinds of business models. And different business models are better at creating shareholder value than others. And some business models are really out of the box.
For three unique examples, consider Riskified NYSE: RSKD), 23andMe (NASDAQ: ME), and Coinbase Global (NASDAQ: COIN). All three have interesting approaches to their respective industries that give them undeniable long-term upside.
Riskified: Zero downside for its customers
Let’s set the stage here: E-commerce is still a red-hot growth industry. According to eMarketer, global e-commerce sales amounted to $4.2 trillion in 2020. But by 2025, global sales could be approaching $7.4 trillion, good for a compound annual growth rate (CAGR) of almost 12%.
The problem for e-commerce companies is that some sales are fraudulent. To prevent this, e-commerce companies can decline suspicious charges. But they risk denying legitimate purchases, hurting their own sales volume in the process.
Enter Riskified stage left. It says that its machine-learning software can increase the amount of purchases that are approved while simultaneously decreasing the amount of fraud that slips through. According to the company, from November 2020 through January 2021, its top 10 customers decreased costs by 39% and increased revenue 8% just by using Riskified.
It processed just $63 billion in sales volume in 2020, or just 1.5% of the total global e-commerce market. So you can certainly see the case for growing its business as it gains market share and as the industry continues its impressive growth trajectory.
► The Daily Money: Get our latest personal finance stories in your inbox
But how can Riskified get more customers? Here’s where the uniqueness of its business model really shines. It offers its clients its Chargeback Guarantee. With this policy, the company promises to increase approval rates, and if fraud gets through, it assumes the cost. In other words, there’s literally zero downside for Riskified’s customers. That’s a hard-to-beat business model, as long as its machine learning is up to the task.
When Riskified’s machine-learning software makes a mistake, the company refunds its customers. Therefore, this expense is listed under cost of revenue, meaning we can track the effectiveness of its software simply by measuring improvements to the company’s gross margin. In the second quarter of 2021, it had a gross profit margin of 60% as opposed to just 53% last year. In other words, it appears the business model is indeed working, making Riskified a stock to take very seriously right now.
23andMe: Getting paid to build its real business
23andMe’s mission statement is “to help people access, understand, and benefit from the human genome.” You’re probably familiar with its genetic testing kits. These help people find out more about themselves, where they come from, and whom they’re related to. Therefore, genetic testing kits speak to two parts of 23andMe’s mission statement: access and understanding.
In the first quarter of 2021, revenue was up 23% year over year to $59 million. All of this revenue came from testing kits and related subscription services. But in my opinion, this part of 23andMe’s business ultimately won’t create meaningful shareholder value. The true value proposition will come from the third aspect of its mission: helping people benefit from the genetic data it has.
Right now, 23andMe is partnering with pharmaceutical companies like GlaxoSmithKline to leverage genetic data into effective drugs. In this particular case, sharing the costs of development could result in a 50/50 split of the profits from a drug to treat cancer, which is currently in phase 1 trials. But this is bigger than one drug: There are currently more than 40 programs underway using 23andMe’s unrivaled genetic data set.
If any of those 40 programs result in a breakthrough medical treatment, 23andMe could enjoy unprecedented growth. And it’s all made possible because it has genetic data that no one else has, and this is what makes the company unique. It didn’t pay to buy this data set – it got paid $59 million in the second quarter by consumers. Therefore, I think it’s fair to say that 23andMe is getting paid by consumers to build a business with a lot of upside, and that should excite investors.
Coinbase Global: Powering a new economy
The cryptocurrency industry didn’t even exist until 2009, so this is a new economy. But it’s staggering to think how far it’s come. According to CoinMarketCap.com, the value of all cryptocurrencies combined is around $2.6 trillion as of this writing.
And consider that this is just the market capitalizations of the cryptocurrencies. There’s far more to this space, including the cryptocurrency mining hardware, ancillary products and services, and non-fungible tokens (NFTs). And Coinbase is looking to power it all everywhere.
► Ethereum is a drug and Cardano is a cheese? If you’re confused by crypto, you’re not alone
► Cryptos are now in 401(k)s: Are they the right investment for your nest egg?
We could focus on Coinbase’s recent announcement to launch an NFT marketplace or how the company was selected to perform custodial services for Facebook‘s new cryptocurrency project. But here I want to discuss something called Coinbase Cloud, which management says is like the cryptocurrency equivalent of Amazon‘s cloud computing business Amazon Web Services (AWS).
Let’s say you have an e-commerce business and want to allow payments by cryptocurrency. Coinbase Cloud can both facilitate the transaction and provide a wallet to store the payment. Or perhaps you want to build a cryptocurrency exchange that competes directly with Coinbase. Yes, Coinbase Cloud could provide everything competitors need to power their own platforms. And given the complexity of supporting hundreds of different cryptocurrencies, it might make a lot of sense to outsource the infrastructure to Coinbase rather than build it from scratch.
It might sound, well, unique, to provide a cloud service that allows competitors to build a product that rivals your own. But this could actually provide Coinbase with long-term upside. If more financial services companies started offering cryptocurrency services, then perhaps long-term adoption would be pushed further than where it is today.
Moreover, Coinbase’s cryptocurrency exchange relies on unreliable trading volume to generate revenue. If it was primarily powering other cryptocurrency exchanges, it would mitigate the uncertainty that comes with trading volume and make revenue more sustainable.
The one for me right now
Riskified, 23andMe, and Coinbase Global have all caught my eye with their uniqueness and long-term potential. However, Riskified is the one I believe is most worthy for inclusion in your portfolio today. Coinbase and 23andMe need small parts of their business to grow in order to be long-term winners, in my opinion. Since that future is less certain, I’d go with Riskified. Its business model is already showing signs that it’s working.
Offer from the Motley Fool
10 stocks we like better than Coinbase Global, Inc.: When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the 10 best stocks for investors to buy right now. .. and Coinbase Global, Inc. wasn’t one of them! That’s right – they think these 10 stocks are even better buys.
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool’s board of directors. Jon Quast has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon, Facebook, and Riskified Ltd. The Motley Fool recommends GlaxoSmithKline and recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.
The Motley Fool is a USA TODAY content partner offering financial news, analysis and commentary designed to help people take control of their financial lives. Its content is produced independently of USA TODAY.